keyword
MENU ▼
Read by QxMD icon Read
search

Dmard therapy

keyword
https://www.readbyqxmd.com/read/29678346/efficacy-of-tocilizumab-in-takayasu-arteritis-multicenter-retrospective-study-of-46-patients
#1
Arsene Mekinian, Mathieu Resche-Rigon, Cloé Comarmond, Alessandra Soriano, Joel Constans, Laurent Alric, Patrick Jego, Florian Busato, Matthieu Cabon, Robin Dhote, Lazaro Estibaliz, Isabelle Kone Pault, Cédric Landron, Christian Lavigne, Bertrand Lioger, Martin Michaud, Marc Ruivard, Karim Sacre, Jacques Eric Gottenberg, Francis Gaches, Tiphaine Goulenok, Carlo Salvarani, Patrice Cacoub, Olivier Fain, David Saadoun
OBJECTIVES: To assess the efficacy of tocilizumab in patients with Takayasu arteritis (TA). METHODS: We conducted a retrospective multicenter study in 46 TA patients treated with tocilizumab. We analyzed factors associated with response to tocilizumab (assessed using NIH score). RESULTS: Forty-six patients with TA were included, with a median age of 43 years [29-54], and 35 (76%) females. We observed a decrease in the median NIH scale (from 3 [2-3] at baseline to 0 [0-1] and 0 at 3 and 6 months, respectively; p < 0...
April 17, 2018: Journal of Autoimmunity
https://www.readbyqxmd.com/read/29668129/-tuberculosis-in-the-era-of-anti-tnf-alpha-therapy-why-does-the-risk-still-exist
#2
John-Leonardo Torres-Castiblanco, Jorge Alberto Carrillo, Daniel Hincapié-Urrego, Adriana Rojas-Villarraga
Rheumatoid arthritis is an autoimmune systemic disease characterized mainly by inflammatory compromise of diarthrodial joints. Multiple drug therapies have been developed to control the activity of rheumatoid arthritis, among them, the first line of disease-modifying antirheumatic drugs (DMARD), and novel drug therapies such as the anti-TNF alpha therapy, with satisfactory clinical outcomes.Despite this positive fact, the use of this therapy implies the risk of producing negative effects due to its mechanism of action, which has been associated with multiple infections, especially tuberculosis, making it necessary to use screen tests before resorting to this kind of drugs...
March 15, 2018: Biomédica: Revista del Instituto Nacional de Salud
https://www.readbyqxmd.com/read/29667551/circulating-mir-10a-as-predictor-of-therapy-response-in-rheumatoid-arthritis-patients-treated-with-methotrexate
#3
Honghai Hong, Haihui Yang, Yong Xia
BACKGROUND: Anti-inflammatory drugs and DMARDs, especially methotrexate, have dramatically improved the outlook of RA patient. However, in some patients the treatment effect is still not satisfactory and needs to change therapeutic regimen in time. So, prediction of patient treatment effect timely is particularly important. METHODS: miRNAs are a large family of highly conserved noncoding genes and some of them become potential biomarker of disease diagnosis. In present study, we found circulating miR-10a was significantly decreased in RA patients compared to osteoarthritic patients and healthy people...
April 17, 2018: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/29667099/analysis-of-relapse-rates-and-risk-factors-of-tapering-or-stopping-pharmacologic-therapies-in-axial-spondyloarthritis-patients-with-sustained-remission
#4
Xiaochan Chen, Ting Zhang, Wenwen Wang, Jing Xue
The objectives of this study are to evaluate whether tapering or stopping strategies of pharmacologic therapies are efficacious for maintaining remission in patients with axial spondyloarthritis (axSPA) and to analyze the risk factors of disease relapse. Patients diagnosed as axSPA with ankylosing spondylitis disease activity score based on C reactive protein (ASDAS-CRP) ≤2.0 for at least 3 months were randomized into three groups: continuing non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs) (group 1), tapering NSAIDs and DMARDs by 50% (group 2), or discontinuing NSAIDs and DMARDs (group3) after 6 months of tapering...
April 18, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29656829/-uveitis-treated-with-biotherapy-and-or-dmard-analysis-from-the-french-pharmacovigilance-study-base
#5
L Cabane, S Baillif, B Baldin, V Breuil, L Euller-Ziegler, N Tieulié
PURPOSE: To report the characteristics of uveitis cases occurring while on biologic therapy or disease-modifying antirheumatic drugs (DMARDs) reported to the French national pharmacovigilance database. METHODS: All the uveitis cases occurring in patients with chronic rheumatologic diseases, chronic inflammatory intestinal diseases or connective tissue diseases, while treated with DMARDs and/or biologic therapies between 2000 and 2015 and reported to the French National Pharmacovigilance Database were collected...
April 13, 2018: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/29649840/-therapeutic-concepts-for-treatment-of-patients-with-non-infectious-uveitis-biologic-disease-modifying-antirheumatic-drugs
#6
Karoline Walscheid, Uwe Pleyer, Arnd Heiligenhaus
Biologic disease modifying antirheumatic drugs (bDMARDs) can be highly efficient in the treatment of various non-infectious uveitis entities. Currently, the TNF-α-inhibitor Adalimumab is the only in-label therapeutic option, whereas, all other bDMARDs need to be given as an off-label therapy. bDMARDs are indicated in diseases refractory to conventional synthetic DMARD therapy and/or systemic steroids, or in patients in whom treatment with those is not possible due to side effects. Therapeutic mechanisms currently employed are cytokine-specific (interferons, inhibition of TNF-α or of interleukin [IL]-1-, IL-6- or IL-17-signalling), inhibit T cell costimulation (CTLA-4 fusion protein), or act via depletion of B cells (anti-CD20)...
April 12, 2018: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/29624580/estimating-the-response-and-economic-burden-of-rheumatoid-arthritis-patients-treated-with-biologic-disease-modifying-antirheumatic-drugs-in-taiwan-using-the-national-health-insurance-research-database-nhird
#7
Qiang Shi, Ko-Jen Li, Tamas Treuer, Bruce C M Wang, Carol L Gaich, Chien-Hsun Lee, Wen-Shuo Wu, Wesley Furnback, Chao-Hsiun Tang
BACKGROUND: Previous studies in Taiwan utilizing the Taiwan's National Health Insurance Database (NHIRD) have estimated the direct healthcare costs of RA patients, but they have not focused on patients on bDMARDs, or considered patients' response to therapy. OBJECTIVES: The objective of this study was to estimate the rate of inadequate response for patients newly treated with biologic disease-modifying antirheumatic drugs (bDMARDs) as well as their costs and resource use...
2018: PloS One
https://www.readbyqxmd.com/read/29623726/the-effect-of-biological-dmards-on-the-risk-of-congestive-heart-failure-in-rheumatoid-arthritis-a-systematic-review
#8
Milad Baniaamam, Walter J Paulus, Annelies B Blanken, Michael T Nurmohamed
A common cardiovascular manifestation in rheumatoid arthritis (RA) is congestive heart failure (CHF) in which inflammation is considered to play a pivotal role. Although anti-inflammatory therapy such as biological disease-modifying anti-rheumatic drugs (bDMARDs) have the potential of improving the cardiac function and reducing the risk of CHF, the published studies showed contrasting results. This review aims to systematically summarize and analyze literature regarding the effect of bDMARDs on the cardiac function and on the risk of CHF in RA...
April 6, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29618121/precision-medicine-using-different-biological-dmards-based-on-characteristic-phenotypes-of-peripheral-t-helper-cells-in-psoriatic-arthritis
#9
Ippei Miyagawa, Shingo Nakayamada, Kazuhisa Nakano, Satoshi Kubo, Shigeru Iwata, Yusuke Miyazaki, Maiko Yoshikawa, Hiroko Yoshinari, Yoshiya Tanaka
Objectives: We sought to investigate the selection of specific biological DMARDs (bDMARDs) based on characteristic lymphocyte phenotypes for treating PsA. Methods: Of 64 patients with PsA resistant to MTX, 26 underwent bDMARDs therapy selected according to phenotypic differences in peripheral helper T cells on 8-colour flow cytometry. The efficacies of this strategic treatment and the standard treatment administered to the other 38 patients were evaluated at 6 months...
April 2, 2018: Rheumatology
https://www.readbyqxmd.com/read/29600931/effects-of-biologic-disease-modifying-anti-rheumatic-drugs-on-the-radiographic-progression-of-rheumatoid-arthritis-a-systematic-literature-review
#10
REVIEW
Bernard Combe, Sadiq Lula, Caroline Boone, Patrick Durez
OBJECTIVES: To evaluate the effect of biologic disease-modifying anti-rheumatic drugs (bDMARDs) on radiographic progression in patients with rheumatoid arthritis (RA). METHODS: A systematic review of electronic databases and conference proceedings was conducted through January 2015, to identify randomised controlled trials (RCTs) and observational studies that assessed the impact of bDMARDs [± conventional synthetic DMARDs (csDMARDs), mainly methotrexate (MTX)], versus csDMARDs alone, on radiographic progression in patients with RA...
March 20, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29595700/starting-of-biological-disease-modifying-antirheumatic-drugs-may-be-postponed-in-rheumatoid-arthritis-patients-with-multimorbidity-single-center-real-life-results
#11
Berkan Armagan, Alper Sari, Abdulsamet Erden, Levent Kilic, Efe Cem Erdat, Saadettin Kilickap, Sedat Kiraz, Sule Apras Bilgen, Omer Karadag, Ali Akdogan, Ihsan Ertenli, Umut Kalyoncu
The objective of this study was to assess the frequency of comorbidities and multimorbidities in rheumatoid arthritis (RA) patients under biologic therapy and their effects on biological disease modifying antirheumatic drugs (DMARDs) choice, timing, and response.Hacettepe University Biologic Registry (HUR-BIO) is single center biological DMARD registry. Cardiovascular, infectious, cancer, and other comorbidities were recorded with face to face interviews. Multimorbidity is defined as >1 comorbidity. Disease duration, initial date of biological DMARDs, initial and overall biological DMARD choice were recorded...
March 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29588576/a-4-year-non-randomized-comparative-phase-iv-study-of-early-rheumatoid-arthritis-integrative-anthroposophic-medicine-for-patients-with-preference-against-dmards-versus-conventional-therapy-including-dmards-for-patients-without-preference
#12
Harald J Hamre, Van N Pham, Christian Kern, Rolf Rau, Jörn Klasen, Ute Schendel, Lars Gerlach, Attyla Drabik, Ludger Simon
Background: While disease-modifying antirheumatic drugs (DMARDs) are a mainstay of therapy for rheumatoid arthritis (RA), some patients with early RA refuse DMARDs. In anthroposophic medicine (AM), a treatment strategy for early RA without DMARDs has been developed. Preliminary data suggest that RA symptoms and inflammatory markers can be reduced under AM, without DMARDs. Patients and methods: Two hundred and fifty-one self-selected patients aged 16-70 years, starting treatment for RA of <3 years duration, without prior DMARD therapy, participated in a prospective, non-randomized, comparative Phase IV study...
2018: Patient Preference and Adherence
https://www.readbyqxmd.com/read/29578852/economic-burden-of-patients-with-inadequate-response-to-targeted-immunomodulators-for-rheumatoid-arthritis
#13
Vibeke Strand, Namita Tundia, Yan Song, Dendy Macaulay, Mahesh Fuldeore
BACKGROUND: Targeted immunomodulators (TIMs), including biologic disease-modifying antirheumatic drugs (DMARDs) and JAK/STAT inhibitors, are effective therapies for rheumatoid arthritis (RA), but some patients fail to respond or lose response over time. This study estimated the real-world prevalence of RA patients with inadequate responses to an initial TIM (nonresponders) in the United States and assessed their direct and indirect economic burden compared with treatment responders. METHODS: Administrative claims data (January 1999-March 2014) from a large private-insurer database were used, which included work-loss data from a subset of reporting companies...
April 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29566769/effectiveness-and-safety-of-tofacitinib-in-rheumatoid-arthritis-a-cohort-study
#14
Marina Amaral de Ávila Machado, Cristiano Soares de Moura, Steve Ferreira Guerra, Jeffrey R Curtis, Michal Abrahamowicz, Sasha Bernatsky
BACKGROUND: Tofacitinib is the first oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA). We compared the effectiveness and safety of tofacitinib, disease-modifying antirheumatic drugs (DMARDs), tumor necrosis factor inhibitors (TNFi), and non-TNF biologics in patients with RA previously treated with methotrexate. METHODS: We used MarketScan® databases (2011-2014) to study methotrexate-exposed patients with RA who were newly prescribed tofacitinib, DMARDs other than methotrexate, and biologics...
March 23, 2018: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29554956/risk-factors-for-oral-methotrexate-failure-in-patients-with-inflammatory-polyarthritis-results-from-a-uk-prospective-cohort-study
#15
James Bluett, Jamie C Sergeant, Alex J MacGregor, Jacqueline R Chipping, Tarnya Marshall, Deborah P M Symmons, Suzanne M M Verstappen
BACKGROUND: Oral methotrexate (MTX) is the first-line therapy for patients with rheumatoid arthritis (RA). However, approximately one quarter of patients discontinue MTX within 12 months. MTX failure, defined as MTX cessation or the addition of another anti-rheumatic drug, is usually due adverse event(s) and/or inefficacy. The aims of this study were to evaluate the rate and predictors of oral MTX failure. METHODS: Subjects were recruited from the Norfolk Arthritis Register (NOAR), a primary care-based inception cohort of patients with early inflammatory polyarthritis (IP)...
March 20, 2018: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29546668/tofacitinib-for-treating-rheumatoid-arthritis-after-the-failure-of-disease-modifying-anti-rheumatic-drugs-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#16
REVIEW
Lesley Uttley, Iñigo Bermejo, Shijie Ren, Marrissa Martyn-St James, Ruth Wong, David L Scott, Adam Young, Matt Stevenson
As part of its Single Technology Appraisal process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Pfizer) of tofacitinib (TOF; Xeljanz® ) to submit evidence of the drug's clinical and cost-effectiveness in the treatment of rheumatoid arthritis (RA) after the failure of conventional disease-modifying antirheumatic drugs (cDMARDs). The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG)...
March 15, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29537146/analyse-der-pharmazeutischen-versorgungssituation-von-patienten-mit-psoriasis-arthritis-auf-basis-von-routinedaten-der-gesetzlichen-krankenversicherung
#17
Wiebke Sondermann, Julia Ventzke, David Matusiewicz, Andreas Körber
HINTERGRUND: Die Psoriasis-Arthritis (PsA) gehört zu den chronisch entzündlichen Gelenkerkrankungen. Trotz zahlreicher versorgungswissenschaftlicher Studien in Deutschland liegen zur pharmazeutischen Versorgungssituation von PsA-Patienten bisher kaum aktuelle Ergebnisse vor. STUDIENPOPULATION UND METHODIK: Mit Hilfe einer systematischen Literaturrecherche sowie anhand von Routinedaten der Allgemeinen Ortskrankenkasse (AOK) Rheinland/Hamburg wird ein aktueller Überblick über die pharmazeutische Versorgung von PsA-Patienten in Deutschland gegeben...
March 2018: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/29532212/predicting-methotrexate-resistance-in-rheumatoid-arthritis-patients
#18
REVIEW
Mary Beth Yu, Anthony Firek, William H R Langridge
Rheumatoid arthritis (RA) is an incurable, systemic autoimmune disease that decreases quality of life and can lead to severe disability. While there are many medications available to treat RA, the first-line of therapy is low-dose methotrexate (MTX), a small molecule disease-modifying anti-rheumatic drug (DMARD). MTX is the recommended therapy due to its affordability and efficacy in reducing symptoms in most RA patients. Unfortunately, there is great person-to-person variability in the physiological response to MTX, with up to 50% of patients showing little response to the medication...
March 12, 2018: Inflammopharmacology
https://www.readbyqxmd.com/read/29526636/optimizing-conventional-dmard-therapy-for-sj%C3%A3-gren-s-syndrome
#19
REVIEW
E H M van der Heijden, A A Kruize, T R D J Radstake, J A G van Roon
No abstract text is available yet for this article.
March 8, 2018: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29490676/pharmacological-characterisation-of-cr6086-a-potent-prostaglandin-e-2-receptor-4-antagonist-as-a-new-potential-disease-modifying-anti-rheumatic-drug
#20
Gianfranco Caselli, Albino Bonazzi, Marco Lanza, Flora Ferrari, Daniele Maggioni, Cristian Ferioli, Roberto Giambelli, Eleonora Comi, Silvia Zerbi, Marco Perrella, Ornella Letari, Elena Di Luccio, Milena Colovic, Stefano Persiani, Tiziano Zanelli, Laura Mennuni, Tiziana Piepoli, Lucio Claudio Rovati
BACKGROUND: Prostaglandin E2 (PGE2 ) acts via its EP4 receptor as a cytokine amplifier (e.g., interleukin [IL]-6) and induces the differentiation and expansion of inflammatory T-helper (Th) lymphocytes. These mechanisms play a key role in the onset and progression of rheumatoid arthritis (RA). We present the pharmacological characterisation of CR6086, a novel EP4 receptor antagonist, and provide evidence for its potential as a disease-modifying anti-rheumatic drug (DMARD). METHODS: CR6086 affinity and pharmacodynamics were studied in EP4-expressing HEK293 cells by radioligand binding and cyclic adenosine monophosphate (cAMP) production, respectively...
March 1, 2018: Arthritis Research & Therapy
keyword
keyword
2404
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"